Cardiff Oncology, Inc. (CRDF) Social Stream
CARDIFF ONCOLOGY INC (CRDF) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CARDIFF ONCOLOGY INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-24 | 4 | $26 | $25 | $25.333 | $1.55 | 1534.39% |
| 2021-12-08 | 5 | $26 | $19 | $23.75 | $1.55 | 1432.26% |
| 2022-01-19 | 6 | $26 | $19 | $23.75 | $1.55 | 1432.26% |
| 2022-02-27 | 6 | $26 | $19 | $22.75 | $1.55 | 1367.74% |
| 2022-04-12 | 6 | $25 | $19 | $22.5 | $1.55 | 1351.61% |
| 2022-05-06 | 6 | $25 | $9 | $18.25 | $1.55 | 1077.42% |
| 2022-05-09 | 6 | $22 | $9 | $17.5 | $1.55 | 1029.03% |
| 2022-05-10 | 6 | $22 | $9 | $15 | $1.55 | 867.74% |
| 2022-05-27 | 6 | $22 | $7 | $11.75 | $1.55 | 658.06% |
| 2022-08-08 | 5 | $22 | $7 | $12.666 | $1.55 | 717.16% |
| 2022-08-29 | 5 | $22 | $6 | $11.666 | $1.55 | 652.65% |
| 2022-09-13 | 5 | $22 | $5 | $11 | $1.55 | 609.68% |
| 2022-09-16 | 5 | $14 | $5 | $8.333 | $1.55 | 437.61% |
| 2023-03-03 | 5 | $14 | $5 | $8 | $1.55 | 416.13% |
| 2023-03-07 | 5 | $15 | $5 | $8.333 | $1.55 | 437.61% |
The Trend in the Analyst Price Target
Over the past 19 months, CRDF's average price target has gone down $15.34.
CRDF reports an average of 690.09% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-12 | 6 | 25 | 19 | 22.500 | 2.08 | 981.73% |
| 2022-05-27 | 5 | 22 | 7 | 11.750 | 1.30 | 803.85% |
| 2022-08-08 | 5 | 22 | 7 | 12.666 | 2.86 | 342.87% |
| 2022-09-27 | 5 | 14 | 5 | 8.000 | 1.55 | 416.13% |
| 2023-03-03 | 5 | 14 | 5 | 8.000 | 1.76 | 354.55% |
CRDF Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 48 weeks, CRDF's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CRDF as an investment opportunity.
- CARDIFF ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 1521.5% of all US stocks.
- CRDF has a lower variance in analysts' estimates than -999.93% of all US stocks.
- CARDIFF ONCOLOGY INC's average analyst price target is higher than 461.31% of Healthcare stocks.
- In the context of stocks in the small market cap category, CARDIFF ONCOLOGY INC's number of analysts covering the stock is greater than 1057.02% of them.
Stocks similar to CARDIFF ONCOLOGY INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are BCLI, CRIS, and AGEN.
View All Top Stocks by Price Target
Is CRDF a Buy, Hold or Sell? See the POWR Ratings now!